ClinicalTrials.gg
Status unknownNCT02871869Updated Jul 17, 2017

Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

A Phase 2/3 interventional study of vindesine and cyclophosphamide in Diffuse, Large B-Cell, Lymphoma, sponsored by Xinjiang Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-07-17.

Sponsored by Xinjiang Medical University · Phase 2/3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
22nd of 211
316 · median 46
Started
2016
with 11 others
Phase 2/3
2 of 218
none open now
Registered
156th of 218
by date

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 22nd largest by planned enrollment of the 211 interventional ones that give a count, is one of 12 that started in 2016, is one of 2 in phase 2/3, and was the 156th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

Diffuse large B cell lymphoma (DLBCL), as the most common subtype non-Hodgkin lymphoma (NHL), has great heterogeneity in clinical manifestations, histological morphology and prognosis. R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone) is the gold therapeutic criteria for patients with NHL, and it is also used as the first-line treatment for patients with DLBCL. After treatment, 50%~60%of patients with DLBCL receive complete remission (CR), 30%~40% recurrent and 10% will never be cured due to initial and secondary drug tolerance. This study aimed to explore whether Cinobufacini Tablets had synergistic effect in the treatment of DLBCL, and whether its action was in close association with the positive expression of Na+/K+-ATPase α3, and to observe the rates of adverse reactions induced by Cinobufacini Tablets during treatment.

Read the detailed description

Diffuse large B cell lymphoma (DLBCL), as the most common subtype non-Hodgkin lymphoma (NHL), accounts for 30%~40% of adults with NHL, and has great heterogeneity in clinical manifestations, histological morphology and prognosis. R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone) is the gold therapeutic criteria for patients with NHL, and it is also used as the first-line treatment for patients with DLBCL. After treatment, 50%~60%of patients with DLBCL receive complete remission (CR), 30%~40% recurrent and 10% will never be cured due to initial and secondary drug tolerance. The study of Tao Wu et al in domestic showed that cinobufacini combined with CHOP protocol had excellent efficacy in the treatment of NHL, with response rate reaching up to 91.7%, and the adverse reactions were mild and tolerable, whereas the response rate of single CHOP was only 62.5%. In the clinical practice of our studies, it was also found that some patients with recurrent DLBCL NHL also had shrunken or disappeared tumors and a survival time of more than 2 years after single administration of cinobufacini tablets for 3\~6 months following the withdrawal of chemotherapy. This study aimed to explore whether Cinobufacini Tablets had synergistic effect in the treatment of DLBCL, and whether its action was in close association with the positive expression of Na+/K+-ATPase α3, and to observe the rates of adverse reactions induced by Cinobufacini Tablets during treatment.

03

Conditions studied

  • Diffuse, Large B-Cell, Lymphoma

Keywords

  • Cinobufacini Tablets
  • CHOP protocol
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For control and trial groups A:

Inclusion Criteria:

  • Patients aged 18-70 years old;
  • Patients with eastern Collaborative Oncology Group () performance status (PS) score: 0~3 points;
  • International prognostic index (IPI): ≤3 points;
  • Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology;
  • Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm);
  • Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, ≥1.5×109/L; (PLT) count ≥100×109/L; (HGB) ≥95g/L; serum (Bil) ≤1.5 folds of the value, (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;
  • Patients with expected survival time>3 months;
  • Patients who were well informed of this study and signed the forms.
  • Patients who received administration of Rituximab.

Exclusion Criteria:

  • Patients who did not conform to above criteria;
  • Patients who were receiving other anti-cancer therapies;
  • Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow;
  • Patients with double expression, double strike, trinary expression and trinary strike and CD5+;
  • Patients complicated with other non-DLBCL primary malignant tumors;
  • Patients who had poor compliance with their families;
  • Patients with one of the following conditions: uncontrolled nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases.
  • Patients had previous history of treatment with Cinobufacini Tablets.

For control and trial groups B

Inclusion Criteria:

  • Patients aged 18-70 years old;
  • Patients with eastern Collaborative Oncology Group (ECOG) performance status (PS) score: 0~3 points;
  • International prognostic index (IPI): ≤3 points;
  • Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology;
  • Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm);
  • Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, neutrophil count ≥1.5×109/L; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) ≥95g/L; serum bilirubin (Bil) ≤1.5 folds of the upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;
  • Patients with expected survival time>3 months;
  • Patients who were well informed of this study and signed the informed consent forms.
  • Patients who did not receive administration of Rituximab.

Exclusion Criteria:

  • Patients who did not conform to above criteria;
  • Patients who were receiving other anti-cancer therapies;
  • Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow;
  • Patients with double expression, double strike, trinary expression and trinary strike and CD5+;
  • Patients complicated with other non-DLBCL primary malignant tumors;
  • Patients who had poor compliance with their families;
  • Patients with one of the following conditions: uncontrolled metastatic nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and refractory hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases.
  • Patients had previous history of treatment with Cinobufacini Tablets.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
316 participants (estimated)

Study arms

  • Active comparator
    Control group A

    Control group A was treated with single R-CHOP protocol\[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: \<4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1~5\], 21 d as a cycle, for 4~6 cycles.

    Drug: vindesine · Drug: cyclophosphamide · Drug: Epirubicin · Drug: prednisone tablets · Drug: Rituximab

  • Experimental
    Trial group A

    Trial group A was treated with Cinobufacini Tablets combined with R-CHOP protocol\[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: \<4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡d1 plus prednisone tablets 100 mg, d1~5\], 21 d as a cycle, for 4~6 cycles.

    Drug: vindesine · Drug: cyclophosphamide · Drug: Epirubicin · Drug: prednisone tablets · Drug: Cinobufacini Tablets · Drug: Rituximab

  • Active comparator
    Control group B

    Control group B was treated with single CHOP protocol\[vindesine 3 mg/㎡ (maximum dosage: \<4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1~5\], 21 d as a cycle, for 4~6 cycles.

    Drug: vindesine · Drug: cyclophosphamide · Drug: Epirubicin · Drug: prednisone tablets

  • Experimental
    Trial group B

    Trial group B was treated with Cinobufacini Tablets combined with CHOP protocol\[vindesine 3 mg/㎡ (maximum dosage: \<4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1~5\], 21 d as a cycle, for 4~6 cycles.

    Drug: vindesine · Drug: cyclophosphamide · Drug: Epirubicin · Drug: prednisone tablets · Drug: Cinobufacini Tablets

Interventions

  • 3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4~6 cycles

    Also known as: eldisine

  • 750 mg/㎡, d1, 21 d as a cycle, for 4~6 cycles

    Also known as: endoxan

  • 60 mg/㎡, d1, 21 d as a cycle, for 4~6 cycles

    Also known as: EPI

  • DrugPrednisoneStudies of PrednisonePrednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    100 mg, d1~5, 21 d as a cycle, for 4~6 cycles

    Also known as: metacortandracin

  • DrugHuachansuStudies of HuachansuHuachansu pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities

    Also known as: buformin

  • 375mg/㎡,one day before CHOP protocol

    Also known as: RTX

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    3-year Progression-free survival (PFS) defined as the ratio of study subjects who had disease progression or died within 3 years from the start of randomization.

    Time frame: 3 years

Secondary outcomes

  1. Overall response rate (ORR)

    Overall response rate (ORR) that defined as the total ratio of study subjects with complete response, complete response unconfirmed and partial response after treatment. ORR=(CR+ CRu+ PR)cases/total cases×100%.

    Time frame: 2 years

  2. overall survival rate (OS)

    3-year overall survival rate (OS) that defined as the ratio of study subjects who survived 3 years after randomization

    Time frame: 3 years

  3. Safety and Tolerability

    Incidence of Treatment-Emergent adverse events

    Time frame: 2 years

  4. Relationship between synergistic effect of Cinobufacini Tablets and expression of Na+/K+-ATPase α3

    Relationship between synergistic effect of Cinobufacini Tablets and expression of Na+/K+-ATPase α3

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital Affiliated to Xinjiang Medical University
    Ürümqi, Xinjiang 830011, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Sep 2018 and a completion of Dec 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2016
First posted
Aug 18, 2016
Start
Sep 2016
Primary completionEst.
Sep 2018
CompletionEst.
Dec 2021
Last update
Jul 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02871869
Lead sponsor
Xinjiang Medical University
Responsible party
Shun-E Yang (Xinjiang Medical University, Xinjiang Medical University) — Principal investigator
First posted
Aug 18, 2016
Start date
Sep 2016
Primary completion
Sep 2018 (estimated)
Completion
Dec 2021 (estimated)
Last update
Jul 17, 2017

Study contacts

Shun-E Yang, Professor
Contact
yangshune@medmail.com.cn
13669926688
Shun-E Yang, Professor
study chair · Cancer Hospital Affiliated to Xinjiang Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Huachansu · Rituximab

Start the discussion